Top

Neda Kalhor, M.D.

Department of Anatomical Pathology, Division of Pathology-Lab Medicine Div

About Dr. Neda Kalhor

I am a board-certified Anatomic and Clinical Pathologist and Cytopathologist, and section chief and medical director of MD Anderson’s Immunohistochemistry Laboratory. My main appointment is to provide interpretation and diagnosis in surgical specimens as well as cytologic material of all body sites and providing results for molecular studies (including mutation analysis and biomarker studies).

I have a broad range of interest in Surgical Pathology and Cytopathology with special interests in Thoracic Tumors. As the Clinical Pathologist for BATTLE-2 Clinical Trial, I was able to incorporate the real-time cytopathology assessment to biopsy procedure to improve diagnostic yield and to generate additional tissue source for biomarker analysis. My expertise in Thoracic Pathology and Cytopathology has provided the opportunity to engage in several multidisciplinary studies at MD Anderson, investigating multiple molecular targets for lung cancer to potentially predict response to chemotherapy and targeted therapy using a variety of tissue preparations and resources.

Primary Appointment

Section Chief, Department of Thoracic Pathology, Division of Pathology-Lab Medicine Div, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1996	Shahid Beheshti University of Medical Sciences, Tehran, IR, MD

Postgraduate Training

2007-2008	Clinical Fellowship, Cytopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2006-2007	Clinical Fellowship, Surgical Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas
2002-2006	Clinical Residency, Anatomic and Clinical Pathology, The University of Texas Health Science Center at Houston Medical School, Houston, Texas
1994-1996	MD, Clinical Internship, Shahid Beheshti University of Medical Sciences, Tehran

Licenses & Certifications

2008	American Board of Cytopathology
2008	Texas Medical License
2006	American Board of Anatomic and Clinical Pathology
2006	Medical License

Experience & Service

Faculty Academic Appointments

Associate Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2019

Assistant Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2014

Administrative Appointments/Responsibilities

Fellowship Director, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - Present

Section chief & Medical Director, Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2015

Other Professional Positions

Thoracic Multidisciplinary Team, Committee Member, MD Anderson, Houston, TX

Senate Promotion & Tenure Issues Committee Member, MD Anderson, Houston, TX

Institutional Review Board Member, MD Anderson, Houston, TX

Advisor, AstraZeneca Pharmaceuticals

Advisor and Steering Committee Member, Merrick and Co., Inc

Member, Faculty Senate, Houston, TX

Member, The University of Texas MD Anderson Cancer Center Institutional Review Board, Houston, TX

Advisor, AbbVie Pharmaceuticals, Inc, Miami, FL

Advisor, Bristol Myers Squibb, USA

Advisor, Roche Diagnostic Corporation, Houston

Extramural Institutional Committee Activities

Member, Clinical Faculty Review Committee-Promotions (CFRC-P), The University of Texas MD Anderson Cancer Center, 2025 - Present

Member, Clinical Competency Committee (CCC), Surgical Pathology, The University of Texas MD Anderson Cancer Center, 2023 - Present

Member, Institutional Review Board 1, The University of Texas MD Anderson Cancer Center, 2015 - 2019

Member, Senate Promotion & Tenure Issues Committee, The University of Texas MD Anderson Cancer Center, 2012 - 2016

Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2012 - 2016

Member, NSCLC GAIN (EnGaging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment & Treatment), The University of Texas MD Anderson Cancer Center, 2011

Chairman, NSCLC eLearning Module Committee, The University of Texas MD Anderson Cancer Center, 2011

Fellowship Committee Member, Surgical Pathology Fellowship Program, The University of Texas MD Anderson Cancer Center, 2009 - 2015

Fellowship Committee Member, Cytopathology Fellowship Program, The University of Texas MD Anderson Cancer Center, 2008 - 2015

Committee Member, Thoracic Multidisciplinary Team, The University of Texas MD Anderson Cancer Center, 2008 - Present

Professional Memberships

Harris County Medical Society

2006 - Present

Texas Medical Association

2006 - Present

American Medical Association

2006 - Present

Texas Society of Pathologist

2004 - Present

United States and Canadian Academy of Pathology

2004 - Present

College of American Pathologists

2003 - Present

American Society for Clinical Pathologists

2003 - Present

Selected Presentations & Talks

Local Presentations

2024. Updates in Thoracic Pathology-Multiple Tumors. Invited. UTHealth Pathology Grand Round. Houston, Texas, US.
2023. Updates in Thoracic Neuroendocrine Tumors. Invited. Annual Diagnostic Pathology Course. Houston, Texas, US.
2022. Updates in Thoracic Pathology. Invited. Annual Diagnostic Pathology Course. Houston, Texas, US.
2015. Mucinous Tumors of the Lung. Invited. Annual Diagnostic Pathology Course. Houston, Texas, US.
2012. Use of Biomarkers to Guide the Treatment of Patients with NSCLC. Invited. Annual Diagnostic Pathology Course. Houston, Texas, US.
2010. Thoracic Unknown Cases. Invited. Houston, Texas, US.

National Presentations

2024. Tissue-Based Multiplexing, Multispectral Immunofluorescence Testing in a CLIA-Like Laboratory Environment: A Step Forward Towards Clinical Testing. Conference. Baltimore, MD, US.
2023. TRPS1 Expression in Neuroendocrine Neoplasms of Breast and Other Organs. Conference. TRPS1 Expression in Neuroendocrine Neoplasms of Breast and Other Organs. New Orleans, LA, US.
2023. Artificial Intelligence-Assisted Tissue Morphology Analysis Reveals the Lymphocytes Infiltration Progression from Lung Preneoplasia to Invasive Adenocarcinoma. Conference. Artificial Intelligence-Assisted Tissue Morphology Analysis Reveals the Lymphocytes Infiltration Progression from Lung Preneoplasia to Invasive Adenocarcinoma. New Orleans, LA, US.
2017. Invited Key Advisor: Roche Molecular Centers of Excellence Tissue Diagnostic Advisory Board. Conference. Invited Key Advisor: Roche Molecular Centers of Excellence Tissue Diagnostic Advisory Board. Indianapolis, IN, US.
2017. Invited Speaker: AbbVie Global Ambition Immersion Program. Conference. Invited Speaker: AbbVie Global Ambition Immersion Program. Chicago, IL, US.
2017. Invited Key Advisor: PD-L1 and Pan Tumor Landscape Advisory Board. Conference. Bristol Myers Squibb Advisory Council Meeting. Chicago, IL, US.
2017. Invited Key Advisor: To discuss Merck's clinical development program for Early Stage Non-Small Cell Lung Cancer. Conference. Merck's Scientific Input Engagement. Clearwater, FL, US.
2017. Invited Speaker: USCAP Thoracic Evening Specialty Conference - "It's in the chest, but it is not lung". Conference. USCAP Thoracic Evening Specialty Conference, 106th USCAP Annual Meeting 2017. San Antonio, TX, US.
2017. Invited Key Advisor: AbbVie SCLC DLL3 Testing Advisory Board. Conference. Invited Key Advisor: AbbVie SCLC DLL3 Testing Advisory Board. Miami, FL, US.
2016. Invited Key Advisor: Pre-AMP Biomarker Advisory Board. Conference. Invited Key Advisor: Pre-AMP Biomarker Advisory Board. Charlotte, NC, US.
2016. Prognostic Factors and Recurrence in Primary Lung Carcinoid Tumor. Conference. Poster Presentation at 105th USCAP Annual Meeting 2016. Seattle, WA, US.
2016. Cell Cycle Progression Score is a Promising Predictor of Recurrence. Conference. Poster Presentation at 105th USCAP Annual Meeting 2016. Seattle, WA, US.
2016. Expression of Programmed Death-Ligand 1 in Small Cell Lung Cancer: Analysis of 48 Cases. Conference. Poster Presentation at 105th USCAP Annual Meeting 2016. Seattle, WA, US.
2016. Combined High-Grade Neuroendocrine Lung Carcinomas: A Clinicopathologic Study of Surgical Resection Cases from a Single Institution. Conference. Poster Presentation at 105th USCAP Annual Meeting 2016. Seattle, WA, US.
2015. Mucinous Tumors of the Lung. Diagnostic Pathology Course. Conference. Mucinous Tumors of the Lung. Diagnostic Pathology Course. Houston, TX, US.
2014. Genomics in Lung Cancer: What Does the Pathologist Want the Clinician to Know?. Conference. The Future of Novel Approaches and Technologies in the Multidisciplinary Management of Cancer Patients. Boston, MA, US.
2014. "Identification of Novel Somatic Variants in Thymic Epithelial Tumors by Next-Generation Sequencing". Conference. "Identification of Novel Somatic Variants in Thymic Epithelial Tumors by Next-Generation Sequencing". San Diego, CA, US.
2014. "Effects of Slide Storage on PTEN Antigenicity: Implications for Clinical Trials and Translational Research". Conference. "Effects of Slide Storage on PTEN Antigenicity: Implications for Clinical Trials and Translational Research". San Diego, CA, US.
2014. "Paraganglioma Versus Thymic Carcinoid Tumor: An Immunohistochemical Study of 46 Cases". Conference. "Paraganglioma Versus Thymic Carcinoid Tumor: An Immunohistochemical Study of 46 Cases". San Diego, CA, US.
2014. "Optimization of a Cell Transfer Technique for Multiple Immunocytochemistry from Single Cytology Smears for Pathology and Translational Research". Conference. "Optimization of a Cell Transfer Technique for Multiple Immunocytochemistry from Single Cytology Smears for Pathology and Translational Research". San Diego, CA, US.
2014. "Primary Mediastinal Seminomas: A Comprehensive Immunohistochemical Study Using Novel Markers". Conference. "Primary Mediastinal Seminomas: A Comprehensive Immunohistochemical Study Using Novel Markers". San Diego, CA, US.
2014. "Localized Malignant Epithelioid Mesothelioma". Conference. "Localized Malignant Epithelioid Mesothelioma". San Diego, CA, US.
2013. "Transcriptomic architecture of the airway field cancerization in early-stage non-small cell lung". Conference. "Transcriptomic architecture of the airway field cancerization in early-stage non-small cell lung", US.
2013. "Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC)". Conference. "Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC)". Chicago, IL, US.
2013. "MECT1-MAML2 Fusion Transcript Expression in Lung Mucoepidermoid Carcinoma". Conference. "MECT1-MAML2 Fusion Transcript Expression in Lung Mucoepidermoid Carcinoma", US.
2013. "Cooper transporter CTR1 expression and tissue platinum concentration in NSCLC". Conference. "Cooper transporter CTR1 expression and tissue platinum concentration in NSCLC". Chicago, IL, US.
2013. "Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC)". Conference. "Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC)". Chicago, IL, US.
2013. "BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC)". Conference. "BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC)". Chicago, IL, US.
2013. "The Impact of Histopathologic Response on Pathologic TNM Lung Cancer Staging System (AJCC 7th) Following Neoadjuvant Chemotherapy". Conference. "The Impact of Histopathologic Response on Pathologic TNM Lung Cancer Staging System (AJCC 7th) Following Neoadjuvant Chemotherapy", US.
2013. "Fibroblast growth factor receptor 1 (FGFR1) gene copy number gain in adenocarcinoma and squamous cell carcinoma of the lung". Conference. "Fibroblast growth factor receptor 1 (FGFR1) gene copy number gain in adenocarcinoma and squamous cell carcinoma of the lung". Chicago, IL, US.
2012. "Diagnostic Pitfalls in Thoracic Tumors". Conference. "Diagnostic Pitfalls in Thoracic Tumors". Boston, MA, US.
2012. "Barriers to the Pathologists". Conference. GAIN (EnGaging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment & Treatment), Regional Summits. Houston, TX, US.
2012. "Gene expression profiling of lung field cancerization reveals potential targets for chemoprevention". Conference. "Gene expression profiling of lung field cancerization reveals potential targets for chemoprevention", US.
2012. "Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential targets for chemoprevention in early stage lung cancer patients". Conference. "Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential targets for chemoprevention in early stage lung cancer patients", US.
2012. "Adenocarcinoma: Radiologic-Pathologic Correlation". Conference. "Adenocarcinoma: Radiologic-Pathologic Correlation", US.
2012. "Feasibility of Molecular Testing in Patients with Chemorefractory Non-Small Cell Carcinoma". Conference. 101st Annual Meeting, US.
2011. "Barriers to the Pathologists". Conference. GAIN (EnGaging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment & Treatment), Regional Summits. Honolulu, HI, US.
2011. "Diagnostic Pitfalls in Lung Cancer Cytology", Update in Surgical Pathology. Conference. "Diagnostic Pitfalls in Lung Cancer Cytology", Update in Surgical Pathology. Seoul.
2011. "Diagnostic Pitfalls in Thoracic Tumors". Conference. "Diagnostic Pitfalls in Thoracic Tumors". Las Vegas, NV, US.
2011. "Malignant Mesothelioma Expresses Melan-A (A-103), a Possible Diagnostic Pitfall". Conference. Platform Presentation at 100th Annual Meeting. San Antonio, TX, US.
2011. "EGFR Mutations in Exons 18, 19, and 21 Are Closely Associated with TTF-1 Positive Lung Adenocarcinoma". Conference. 100th Annual Meeting. San Antonio, TX, US.
2011. "Molecular abnormalities associated to the progression of lung adenocarcinomas with BAC features from non-invasive to invasive patterns". Conference. 102nd Annual Meeting. Chicago, IL, US.
2011. "Identification of prostate stem cell antigen (PSCA) as a potential marker for lung cancer brain metasis". Conference. 102nd Annual Meeting. Chicago, IL, US.
2011. "High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and EGFR Mutation". Conference. 100th Annual Meeting. San Antonio, TX, US.
2010. "Mucinous Carcinoma (Colloid Carcinoma) of the Lung, an Immunohistochemical and Molecular Analysis". Conference. Platform Presentation at 99th Annual Meeting. Boston, MA, US.

International Presentations

2026. Diagnostic Challenges in the Evaluation of Pleural Neoplasms. Invited. Peruvian Association of Pathologists. Cusco, PE.
2026. Diagnostic Approach to Tumors of the Anterior Mediastinum. Invited. Peruvian Association of Pathologists. Cusco, PE.
2026. Pitfalls and Key Features for the Accurate Diagnosis of Lung Carcinomas. Invited. Peruvian Association of Pathologists. Cusco, PE.
2024. Digital & Computational Pathology for a novel ADC Biomarker Advisory Board ESMO. Invited. ESMO. Barcelona, ES.
2017. Invited Speaker: "Biomarkers in Lung Carcinoma". Conference. 3rd International Refresher Course in Surgical Pathology. Guatemala, GT.
2017. Invited Speaker: Oncologic Surgical Pathology Course - "Molecular Biology of Pulmonary Carcinoma". Conference. Mexican Pathology Association. Mexico City, MX.
2016. Invited Speaker: 'Immunohistoquimica Aplicada' -. Conference. 2nd International Refresher Course in Surgical Pathology. Guatemala City, GT.
2015. Clinico-pathological implications of GI neuroendocrine tumors. Conference. 2nd Int'l Gastrointestinal Cancers Congress. Tehran, IR.
2015. EUS-FNA biopsy and pitfalls. Conference. 2nd International Gastrointestinal Cancer Congress. Tehran, IR.
2015. Molecular Markers in Lung Cancer. Conference. Molecular Markers in Lung Cancer. Guatemala City, GT.
2014. "Contemporary Issues in Thoracic Pathology", New and Evolving Concepts Symposium. Conference. "Contemporary Issues in Thoracic Pathology", New and Evolving Concepts Symposium. Sydney, AU.
2013. "Cytology and Surgical Pathology Correlations: Pitfalls and Shortcomings". The 2013 International Diagnostic Pathology Course. Conference. "Cytology and Surgical Pathology Correlations: Pitfalls and Shortcomings". The 2013 International Diagnostic Pathology Course. Tokyo, JP.
2011. "Diagnostic Methods in Lung Ca, Role of cytology, intraoperative biopsy and immunohistochemistry". Conference. New Borders in Lung Cancer, Clinica Alemana. Santiago, CL.
2011. "Correlation between Tissue Platinum Concentration and Tumor Response in NSCLC". Conference. 14th World Conference on Lung Cancer. Amsterdam, NL.
2011. "Diagnostic Pitfalls in Lung Cancer Cytology". Conference. Department of Diagnostic Pathology Juntendo University Nerima Hospital. Tokyo, JP.
2010. "Pancytokeratin, cytokeratin 5/6, cytokeratin 7, cytokeratin 20, TTF-1 and p63 as a diagnostic tool separating non-small cell carcinomas in biopsy specimens". Conference. poster presentation at XXVIIIth International Congress of the International Academy of Pathology. Sao Paolo, BR.
2010. "Spindle cell thymomas: an immunohistochemical study of 30 cases". Conference. poster presentation at XXVIIIth International Congress of the International Academy of Pathology. Sao Paolo, BR.
2010. "Pleural malignant mesothelioma with prominent adenomatoid features: clinicopathological and immunohistochemical analysis of 10 cases". Conference. poster presentation at XXVIIIth International Congress of the International Academy of Pathology. Sao Paolo, BR.
2010. "Thoracic Pathology Case Discussion". Conference. "Thoracic Pathology Case Discussion". San Jose, CR.
2010. "Interpretation and Work Up of Lung Biopsies". Conference. "Interpretation and Work Up of Lung Biopsies". San Jose, CR.
2010. "Pathology of Pulmonary Neuroendocrine Tumors". Conference. "Pathology of Pulmonary Neuroendocrine Tumors". San Jose, CR.
2009. "Pathology of Pulmonary Neuroendocrine Tumors". Conference. The 2009 International Diagnostic Pathology Course. Tokyo, JP.

Formal Peers

2024. Mesothelioma, updates and diagnostic challenges. Tehran, IR.
2024. Patient Identification Paradigm in Resectable NSCLC. Invited. Las Vegas, NV, US.
2024. Primary tracheal Adamantinoma-like Ewing sarcoma (ALES). Poster. Las Vegas, NV, US.
2024. Diagnostic challenges in thoracic tumors, case review. Invited. Barcelona, ES.
2024. Updates in Thoracic Pathology-Multiple Tumors. Conference. Baltimore, MD, US.
2024. Updates in Thoracic Neuroendocrine Tumors. Houston, Texas, US.
2023. Diagnostic challenges in Neuroendocrine Tumors. Houston, Texas, US.
2022. Diagnostic challenges in Neuroendocrine Tumors. Houston, Texas, US.
2022. Updates in Thoracic Pathology. Houston, Texas, US.
2020. Endobronchial Ultrasound guided Fine Needle Aspiration and Biopsy, Hawaii, US.
2020. Pleural Mesothelioma, Hawaii, US.
2019. Requirements for Tumor Biopsies in the age of Precision Cancer Care: Pathologist’s Perspective. Chicago, Illinois, US.
2019. Pulmonary Neuroendocrine Tumors”, New and Evolving Concepts in Surgical Pathology. Pullman Bunker Bay, , Naturaliste, AU.
2019. Biomarker Testing in Lung Cancer. Guatemala City, GT.
2019. Pathology of Malignant Mesothelioma; an Update. Napa Valley, California, US.
2019. Pulmonary Neuroendocrine Tumors. Napa Valley, California, US.
2019. Pathology of Lung Neuroendocrine Tumors. Mexico City, MX.
2019. Diagnostic Pitfalls in Thoracic Pathology. Houston, Texas, US.
2018. Biomarkers in Lung Cancer. San Salvador, SV.
2018. New AJCC 8th Lung Cancer Staging. New Orleans, LA, US.
2018. Oncologic Surgical Pathology Course- “Endobronchial Ultrasound Guided Fine Needle Aspiration. Mexico City, MX.
2018. Endobronchial Ultrasound Guided Fine Needle Aspiration. Antigua, Texas, GT.
2017. Biomarkers in Lung Carcinoma. Guatemala City, GT.
2017. It's in the chest, but it is not lung. San Antonio, Texas, US.
2017. Molecular Biology of Pulmonary Carcinoma. Mexicao City, MX.
2016. Immunohistoquimica Aplicada. Guatemala City, GT.
2016. Grand Rounds: Biomarker Testing in Lung Cancer. Invited. New York, NY, US.
2015. Clinico-pathological implications of GI neuroendocrine tumors. Tehran, IR.
2015. EUS-FNA biopsy and its pitfalls. Tehran, IR.
2015. Molecular Markers in Lung Cancer. Guatemala City, GT.
2015. Mucinous Tumors of the Lung. Houston, Texas, US.
2014. Genomics in Lung Cancer: What Does the Pathologist Want the Clinician to Know?” The Future of Novel Approaches and Technologies in the Multidisciplinary Management of Cancer Patients. Boston, MA, US.
2014. Contemporary Issues in Thoracic Pathology. Sydney, AU.
2013. Cytology of Pulmonary Neuroendocrine Tumors. Tokyo, JP.
2012. Diagnostic Pitfalls in Thoracic Tumors. Boston, MA, US.
2011. Diagnostic Methods in Lung Cancer, Role of cytology, intraoperative biopsy and immunohistochemistry," New Borders in Lung Cancer. Santiago, CL.
2011. Diagnostic Pitfalls in Lung Cancer Cytology, Update in Surgical Pathology. Daegu, KR.
2010. Thoracic Pathology Case Discussion. San Jose, CL.
2010. Pathology of Pulmonary Neuroendocrine Tumors. San Jose, CL.
2010. Interpretation and Work Up of Lung Biopsies. San Jose, CL.
2009. Pathology of Pulmonary Neuroendocrine Tumors. Tokyo, JP.

Less

Grant & Contract Support

Date:	2026 - 2031
Title:	Cell-type specific dissection of protumor inflammatory pathways driving KRAS-mutant lung adenocarcinoma to guide the development of novel preventive and therapeutic strategies
Funding Source:	NIH/NCI
Role:	Co-I
ID:	14476562

Date:	2025 - 2028
Title:	Targeting Immune-Epithelial Interaction for Lung Cancer Prevention and Therapy
Funding Source:	CPRIT
Role:	Co-I
ID:	RP260039/FP00025874

Date:	2024 - 2027
Title:	Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer
Funding Source:	CPRIT
Role:	Co-I
ID:	FP00016814_Res1/RP240117

Date:	2022 - 2027
Title:	Radioimmunogenomic analysis of indeterminant pulmonary nodules for precision immunoprevention of lung cancer
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	1R01CA269475.01

Date:	2022 - 2026
Title:	Radioimmunogenomic analysis of indeterminant pulmonary nodules for precision immuno prevention of lung cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP220374

Date:	2017 - 2022
Title:	Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5U01CA213273-04 Revised

Date:	2017 - 2024
Title:	Phase II Trial of Adcetris (brentuximab vedotin) in CD30+ malignant Mesothelioma
Funding Source:	Seattle Genetics
Role:	Collaborator
ID:	2016-0514

Date:	2015 - 2020
Title:	Overcoming Resistance to Anti-EGFRZ Therapy by Drug Repurposing
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5-R01CA-CA190628-03

Date:	2014 - 2019
Title:	UT Spore in Lung Cancer
Funding Source:	University of Texas Southwestern Medical Center-Dallas
Role:	Collaborator
ID:	5P50CA070907-19

Date:	2014 - 2019
Title:	University of Texas SPORE (Special Programs of Research Excellence) in Lung Cancer Developing New Rationale, Personalized Medicine for Lung Cancer Developing New Rationale, Personalized Medicine for Lung Cancer
Funding Source:	NIH/NCI
Role:	Co-Investigator Project 3
ID:	5P50 CA70907-18

Date:	2014 - 2019
Title:	University of Texas Spore in Lung Cancer (Leader of Core B)
Funding Source:	UT Southwestern Medical (Subcontract)
Role:	Co-I
ID:	5 P50 CA070907 17

Date:	2013 - 2014
Title:	Molecular profiles for lung cancer pathogenesis and detection in US veterans
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	W81XWH-10-1-1007

Date:	2013 - 2014
Title:	UT SPORE in Lung Cancer- Year 15 Supplement- Project 3
Funding Source:	University of Texas Southwestern Med Ctr-Dallas
Role:	Co-I

Date:	2012 - 2018
Title:	Molecular Profiling of Lung Cancer
Funding Source:	Myriad Genetics (Master Agreement)
Role:	Co-I
ID:	LS2009-00027144JW 02

Date:	2012 - 2017
Title:	Carcinoid Lung Cancer Study
Funding Source:	Myriad Genetics, Inc
Role:	Co-I
ID:	LAB90-020

Date:	2012 - 2017
Title:	Carcinoid Lung Cancer Study
Funding Source:	NIH/NCI
Role:	Co-I
ID:	LAB90-020

Date:	2012 - 2014
Title:	UT Spore in Lung Cancer
Funding Source:	University of Texas Southwestern Medical Center
Role:	Co-I
ID:	5P50CA070907-15S1

Date:	2010 - 2014
Title:	A Biomarker-integrated Study in Previously Treated Patients with Non-Small Cell Lung Cancer (BATTLE-II)
Funding Source:	Merck and Company
Role:	Co-I
ID:	CS2011-00033943LG 01

Date:	2010 - 2014
Title:	Molecular profiles for lung cancer pathogenesis and detection in US
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	W81XWH-09-LCRP-CTRA 01

Date:	2007 - 2013
Title:	Spore in Lung Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5-P50-CA70907-14

Date:	2006 - 2012
Title:	BATTLE
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	W81XWH-06-1-0303

Selected Publications

Peer-Reviewed Articles

Peng, F, Sinjab, A, Dai, Y, Treekitkarnmongkol, W, Yang, S, Gomez Bolanos, L, Zhou, T, Chen, M, Serrano, A, Krishna, A, Karimi, N, Sharma, M, Basi, A, Pei, G, Liao, J, Liu, Y, Feng, J, Rahal, Z, Liu, Y, Jiang, J, Yu, K, Noun, T, Liu, Y, Khan, KB, Cho, KS, Chen, J, Solis Soto, LM, Mazzilli, SA, Dubinett, SM, Cascone, T, Spira, A, Swisher, SG, Jimbo, N, Hayashi, T, Kishikawa, S, Takamochi, K, Itoh, T, Yao, T, Suzuki, K, Kalhor, N, Wistuba, II, Li, M, Moghaddam, SM, Fujimoto, J, Burks, JK, Myers, JN, Akdemir, KC, Wang, L, Kadara, HN. Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions. Cancer cell 44(2):321-339.e13, 2026. e-Pub 2026. PMID: 41202811.
Ye Q, Estrella J, Kalhor N, Liu A, Han C, Sun H, Middleton LP, Chen H, Albarracin C, Sahin A, Wu Y, Ding Q. TRPS1 expression in neuroendocrine neoplasms of breast and other organs. Histopathology 88(2):524-532, 2025. e-Pub 2025. PMID: 41025885.
Feng, P, Kalhor, N. Multimodal Spatial-OMICS Reveal CO-Evolution of Alveolar Progenitors and Proinflammatory Niches in Progression of Lung Precursor Lesions. Cancer Cell, 2025.
Cooper, AJ, Arfe, A, Ricciuti, B, Gagné, A, Sholl, LM, Di Federico, A, Awad, MM, Aldea, M, Ghigna, MR, Grecea, M, Clark, P, Chaft, JE, Kris, MG, Riely, GJ, Rudin, CM, Dagogo-Jack, I, Mino-Kenudson, M, Hong, L, Kalhor, N, Vokes, N, Bowman, AS, Yang, SR, Rekhtman, N, Schoenfeld, AJ. Brief Report. JTO Clinical and Research Reports 6(1), 2025. e-Pub 2025. PMID: 39802817.
Serrano, A, Rocha, P, Freitas Lima, C, Stewart, A, Zhang, B, Diao, L, Fujimoto, J, Cardnell, R, Lu, W, Khan, KB, Sable, B, Ellison, AR, Wistuba, II, Concannon, KF, Halperin, DM, Czerniak, BA, Sircar, K, Zhang, M, Cargill, KR, Wang, Q, Aparicio, A, Lazar, A, Hernandez, S, Estrella, JS, Ramalingam, P, El-Naggar, AK, Kalhor, N, Gay, CM, Byers, LA, Solis Soto, LM. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39558076.
Stewart CA, Diao L, Xi Y, Wang R, Ramkumar K, Serrano AG, Tanimoto A, Rodriguez BL, Morris BB, Shen L, Zhang B, Yang Y, Hamad SH, Cardnell RJ, Duarte A, Sahu M, Novegil VY, Weissman BE, Frumovitz M, Kalhor N, Solis Soto L, da Rocha P, Vokes N, Gibbons DL, Wang J, Heymach JV, Glisson B, Byers LA, Gay CM. YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities. Clin Cancer Res 30(20):4743-4754, 2024. e-Pub 2024. PMID: 39150543.
Mosaffa SL, Eapen G, Kalhor N, Sneige N. Non-small cell lung carcinoma with ectopic gonadotropin production: A case report and review of the literature. Diagn Cytopathol 52(7):397-399, 2024. e-Pub 2024. PMID: 38576061.
Seth, S, Chen, R, Liu, Y, Fujimoto, J, Hong, L, Reuben, A, Varghese, S, Behrens, MC, McDowell, TL, Solis Soto, LM, Haymaker, CL, Weissferdt, A, Kalhor, N, Wu, J, Le, X, Vokes, N, Cheng, C, Heymach, JV, Gibbons, DL, Futreal, A, Wistuba, II, Kadara, HN, Zhang, J, Moran, C, Zhang, J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innovation 3(3), 2024. e-Pub 2024. PMID: 38947760.
Salem A, Wu Y, Albarracin CT, Middleton LP, Kalhor N, Peng Y, Huang X, Aung PP, Chen H, Sahin AA, Ding Q. A Comparative Evaluation of TRPS1 and GATA3 in adenoid cystic, secretory, and acinic cell carcinomas of the breast and salivary gland. Hum Pathol 145:42-47, 2024. e-Pub 2024. PMID: 38262580.
Chen P, Rojas FR, Hu X, Serrano A, Zhu B, Chen H, Hong L, Bandyoyadhyay R, Aminu M, Kalhor N, Lee JJ, El Hussein S, Khoury JD, Pass HI, Moreira AL, Velcheti V, Sterman DH, Fukuoka J, Tabata K, Su D, Ying L, Gibbons DL, Heymach JV, Wistuba II, Fujimoto J, Solis Soto LM, Zhang J, Wu J. Pathomic Features Reveal Immune and Molecular Evolution from Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol 36(12), 2023. e-Pub 2023. PMID: 37678674.
Diao S, Chen P, Showkatian E, Bandyopadhyay R, Rojas FR, Zhu B, Hong L, Aminu M, Saad MB, Salehjahromi M, Muneer A, Sujit SJ, Behrens C, Gibbons DL, Heymach JV, Kalhor N, Wistuba II, Solis Soto LM, Zhang J, Qin W, Wu J. Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835518.
Lizarraga Madrigal D, Cabrera Charleston M, Khan A, Eapen G, Kalhor N, Gan Q, Grosu H. Pulmonary Sclerosing Pneumocytomas Mimicking Lung Cancer. Cureus 15(4):e37395, 2023. e-Pub 2023. PMID: 37182004.
Francisco-Cruz A, Rocha P, Reuben A, Krishnan SN, Das P, Chen R, Quek K, Li J, Parra ER, Solis LM, Barua S, Jiang M, Lazcano R, Chow CW, Behrens C, Gumb C, Little L, Fukuoka J, Kalhor N, Weissferdt A, Kadara H, Heymach JV, Swisher S, Sepesi B, Rao A, Moran C, Zhang J, Lee JJ, Fujimoto J, Futreal PA, Wistuba II, Peterson CB, Zhang J. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol 36(1), 2023. e-Pub 2023. PMID: 36788067.
Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer 172:19-28, 2022. e-Pub 2022. PMID: 35973335.
Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1965-1976, 2021. e-Pub 2021. PMID: 33416944.
Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1977-1978, 2021. e-Pub 2021. PMID: 33686493.
Zaleski M, Kalhor N, Moran CA. Typical and Atypical Carcinoid Tumors of the Mediastinum: A Biomarker Analysis of 27 Cases With Clinical Correlation. Int J Surg Pathol 29(4):358-367, 2021. e-Pub 2021. PMID: 33243039.
Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol 76(2):155.e25-155.e34, 2021. e-Pub 2021. PMID: 33268083.
Zaleski M, Kalhor N, Fujimoto J, Wistuba I, Moran CA. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1. Pathol Res Pract 216(12):153267, 2020. e-Pub 2020. PMID: 33176261.
Zaleski MP, Kalhor N, Moran CA. Mucous Gland Adenoma: The Spectrum of Growth Patterns and the Diagnostic Challenges. Adv Anat Pathol 27(6):371-379, 2020. e-Pub 2020. PMID: 32909967.
Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
Cherng HJ, Jain N, Thakral B, Muzzafar T, Miranda RN, Tan D, Rashid A, Kalhor N, Hahn AW, Byers LA, Parseghian CM, Ferrajoli A, Pemmaraju N. Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leuk Res 98:106445, 2020. e-Pub 2020. PMID: 32937250.
Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 2020. e-Pub 2020. PMID: 32193228.
Weissferdt A, Pataer A, Vaporciyan AA, Correa AM, Sepesi B, Moran CA, Wistuba II, Roth JA, Shewale JB, Heymach JV, Kalhor N, Cascone T, Hofstetter WL, Lee JJ, Swisher SG. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer 21(4):341-348, 2020. e-Pub 2020. PMID: 32279936.
Cruz L, Martinez Zayas G, Kalhor N, Grosu HB. Primary Tracheal Melanoma. J Bronchology Interv Pulmonol 27(3):e47-e48, 2020. e-Pub 2020. PMID: 32569080.
Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer 1:423-436, 2020. e-Pub 2020. PMID: 33521652.
Nelson DB, Mitchell KG, Wang J, Fujimoto J, Godoy M, Behrens C, Zheng X, Zhang J, Sepesi B, Vaporciyan AA, Hofstetter WL, Mehran RJ, Rice DC, Walsh GL, Swisher SG, Moran CA, Kalhor N, Weissferdt A, Wistuba II, Roth JA, Antonoff MB. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis 12(3):329-337, 2020. e-Pub 2020. PMID: 32274099.
Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas HA, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clin Cancer Res 26(4):892-901, 2020. e-Pub 2020. PMID: 31694833.
Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
Datar S, De La Garza H, Srinivasan A, Iliescu G, Kalhor N, Grosu H. Invasive Thymoma with Right Upper Lobe Endobronchial Lesion and Autoimmune Enteropathy. Case Rep Pulmonol 2020:6396915, 2020. e-Pub 2020. PMID: 32637181.
Wang S, Wang T, Yang L, Yang DM, Fujimoto J, Yi F, Luo X, Yang Y, Yao B, Lin S, Moran C, Kalhor N, Weissferdt A, Minna J, Xie Y, Wistuba II, Mao Y, Xiao G. ConvPath: A software tool for lung adenocarcinoma digital pathological image analysis aided by a convolutional neural network. EBioMedicine 50:103-110, 2019. e-Pub 2019. PMID: 31767541.
Hamza A, Younes AI, Kalhor N. Thymic Mucoepidermoid Carcinoma: A Systematic Review and Meta-analysis. Adv Anat Pathol 26(6):341-345, 2019. e-Pub 2019. PMID: 31593977.
Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. Am J Respir Crit Care Med 200(6):742-750, 2019. e-Pub 2019. PMID: 30896962.
Monroig-Bosque PDC, Morales-Rosado JA, Roden AC, Churg A, Barrios R, Cagle P, Ge Y, Allen TC, Smith ML, Larsen BT, Sholl LM, Beasley MB, Borczuk A, Raparia K, Ayala A, Tazelaar HD, Miller R, Kalhor N, Moran CA, Ro JY. Micropapillary adenocarcinoma of lung: Morphological criteria and diagnostic reproducibility among pulmonary pathologists. Ann Diagn Pathol 41:43-50, 2019. e-Pub 2019. PMID: 31132651.
Luo X, Yin S, Yang L, Fujimoto J, Yang Y, Moran C, Kalhor N, Weissferdt A, Xie Y, Gazdar A, Minna J, Wistuba II, Mao Y, Xiao G. Development and Validation of a Pathology Image Analysis-based Predictive Model for Lung Adenocarcinoma Prognosis - A Multi-cohort Study. Sci Rep 9(1):6886, 2019. e-Pub 2019. PMID: 31053738.
Kalhor N, Moran CA. Thymic epithelial neoplasms with sebaceous differentiation: a clinicopathological and immunohistochemical study of 8 cases. Hum Pathol 86:124-128, 2019. e-Pub 2019. PMID: 30537491.
Mann S, Khawar S, Moran C, Kalhor N. Revisiting localized malignant mesothelioma. Ann Diagn Pathol 39:74-77, 2019. e-Pub 2019. PMID: 30798074.
Kalhor N, Moran CA. Thymic epithelial neoplasms with rhabdomyomatous component: a clinicopathological and immunohistochemical study of 7 cases. Hum Pathol 83:100-105, 2019. e-Pub 2019. PMID: 30217623.
Kalhor N, Moran CA. Thymomas With a Prominent Alveolar Growth Pattern: A Clinicopathologic and Immunohistochemical Study of 12 Cases. Am J Clin Pathol 151(2):171-175, 2019. e-Pub 2019. PMID: 30247496.
Lindholm KE, Kalhor N, Moran CA. Osteoclast-like giant cell rich carcinomas of the lung: a Clinicopathological, Immunohistochemical, and molecular study of three cases. Hum Pathol. e-Pub 2018. PMID: 30447297.
Ruder D, Papadimitrakopoulou V, Shien K, Behrens C, Kalhor N, Chen H, Shen L, Lee JJ, Hong WK, Tang X, Girard L, Minna JD, Diao L, Wang J, Mino B, Villalobos P, Rodriguez-Canales J, Hanson NE, Sun J, Miller V, Greenbowe J, Frampton G, Herbst RS, Baladandayuthapani V, Wistuba II, Izzo JG. Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of RICTOR/KRAS-altered non-small cell lung cancer. Oncotarget 9(74):33995-34008, 2018. e-Pub 2018. PMID: 30338041.
Guo M, Khanna A, Wang J, Williams MD, Kalhor N, Gong Y, Xu L, Sturgis EM, Staerkel G. Incorporation of Cervista Human Papillomavirus 16/18 Assay Into Algorithms for Classifying Human Papillomavirus Status in Formalin-Fixed Paraffin-Embedded Head and Neck Squamous Carcinoma Specimens. Arch Pathol Lab Med. e-Pub 2018. PMID: 30221979.
Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8(7):822-835, 2018. e-Pub 2018. PMID: 29773717.
Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6(1):48, 2018. e-Pub 2018. PMID: 29871672.
Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II. Immunohistochemical and Image Analysis-based Study Demonstrate that Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol 13(6):779-791, 2018. e-Pub 2018. PMID: 29526824.
Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 31(6):947-955, 2018. e-Pub 2018. PMID: 29410488.
Noll B, Wang WL, Gong Y, Zhao J, Kalhor N, Prieto V, Staerkel G, Roy-Chowdhuri S. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations. Cancer Cytopathol 126(5):342-352, 2018. e-Pub 2018. PMID: 29499101.
Kalhor N, Moran CA. Primary thymic adenocarcinomas: a clinicopathological and immunohistochemical study of 16 cases with emphasis on the morphological spectrum of differentiation. Hum Pathol 74:73-82, 2018. e-Pub 2018. PMID: 29339175.
Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol 29(4):1072, 2018. e-Pub 2018. PMID: 29688333.
Gomez DR, Byers LA, Nilsson M, Diao L, Wang J, Li L, Tong P, Hofstad M, Saigal B, Wistuba I, Kalhor N, Swisher S, Fan Y, Hong WK, Suraokar M, Behrens C, Moran C, Heymach JV. Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget 9(18):14268-14284, 2018. e-Pub 2018. PMID: 29581842.
Weissferdt A, Kalhor N, Bishop JA, Jang SJ, Ro J, Petersson F, Wu B, Langman G, Bancroft H, Bi Y, Meng Y, Medeiros F, Brunnstrom H, Spagnolo D, Chai SM, Laycock A, Wakely PE, Elmberger G, Soares FA, Campos AH, Gumurdulu D, Alvarado-Cabrero I, Coppola D, Correa AM, Rice D, Mehran RJ, Sepesi B, Walsh G, Kaiser L, Moran CA. Thymoma: a clinicopathological correlation of 1470 cases. Hum Pathol 73:7-15, 2018. e-Pub 2018. PMID: 28851660.
Kalhor N, Moran CA. Pulmonary mucoepidermoid carcinoma: diagnosis and treatment. Expert Rev Respir Med 12(3):249-255, 2018. e-Pub 2018. PMID: 29338644.
Cascone T, Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105(2):418-424, 2018. e-Pub 2018. PMID: 29217088.
Fang L, Chen H, Tang Z, Kalhor N, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR, Routbort MJ, Hong D, Medeiros LJ, Lu X. MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget 9(16):12959-12970, 2018. e-Pub 2018. PMID: 29560123.
Khoury JD, Wang WL, Prieto VG, Medeiros LJ, Kalhor N, Hameed M, Broaddus R, Hamilton SR. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. Clin Cancer Res 24(3):521-531, 2018. e-Pub 2018. PMID: 28839110.
Shien K, Papadimitrakopoulou VA, Ruder D, Behrens C, Shen L, Kalhor N, Song J, Lee JJ, Wang J, Tang X, Herbst RS, Toyooka S, Girard L, Minna JD, Kurie JM, Wistuba II, Izzo JG. JAK1/STAT3 activation through a proinflammatory cytokine pathway leads to resistance to molecularly targeted therapy in non-small cell lung cancer. Mol Cancer Ther 16(10):2234-2245, 2017. e-Pub 2017. PMID: 28729401.
Wadhwa R, Wang X, Baladandayuthapani V, Liu B, Shiozaki H, Shimodaira Y, Lin Q, Elimova E, Hofstetter WL, Swisher SG, Rice DC, Maru DM, Kalhor N, Bhutani MS, Weston B, Lee JH, Skinner HD, Scott AW, Kaya DM, Harada K, Berry D, Song S, Ajani JA. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer 117(5):648-655, 2017. e-Pub 2017. PMID: 28728163.
Adams DL, Adams DK, He J, Kalhor N, Zhang M, Xu T, Gao H, Reuben JM, Qiao Y, Komaki R, Liao Z, Edelman MJ, Tang CM, Lin SH. Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy. Clin Cancer Res. e-Pub 2017. PMID: 28679765.
Miller R, Mudambi L, Vial MR, Kalhor N, Grosu HB. Radiation-induced Angiosarcoma as a Cause of Pleural Effusion. Am J Respir Crit Care Med. e-Pub 2017. PMID: 28510475.
Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, Yenerall P, Zhou Y, Timmons BC, Rodriguez-Canales J, Behrens C, Mino B, Villalobos P, Parra ER, Suraokar M, Pataer A, Swisher SG, Kalhor N, Bhanu NV, Garcia BA, Heymach JV, Coombes K, Xie Y, Girard L, Gazdar AF, Kittler R, Wistuba II, Minna JD, Martinez ED. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Rep 19(8):1669-1684, 2017. e-Pub 2017. PMID: 28538184.
Sepesi B, Cuentes EP, Canales JR, Behrens C, Correa A, Antonoff M, Gibbons DL, Heymach J, Hofstetter W, Mehran R, Rice DC, Roth J, Vaporciyan AA, Walsh G, Weissferdt A, Kalhor N, Moran C, Swisher SG, Wistuba I. Tumor-Infiltrating Lymphocytes and Overall Survival in Surgically Resected Stage II and III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 98(1):223, 2017. e-Pub 2017. PMID: 28586974.
Weissferdt A, Kalhor N, Moran CA. Cutaneous basal cell carcinoma with distant metastasis to thorax and bone : A clinicopathological and immunohistochemical study of 15 cases. Virchows Arch. e-Pub 2017. PMID: 28391557.
Weissferdt A, Fujimoto J, Kalhor N, Rodriguez J, Bassett R, Wistuba II, Moran CA. Expression of PD-1 and PD-L1 in thymic epithelial neoplasms. Mod Pathol. e-Pub 2017. PMID: 28281549.
Salem A, Bell D, Sepesi B, Papadimitrakopoulou V, El-Naggar A, Moran CA, Kalhor N. Clinicopathologic and genetic features of primary bronchopulmonary mucoepidermoid carcinoma: the MD Anderson Cancer Center experience and comprehensive review of the literature. Virchows Arch. e-Pub 2017. PMID: 28343305.
Kalhor N, Weissferdt A, Moran CA. Primary Salivary Gland Type Tumors of the Thymus. Adv Anat Pathol 24(1):15-23, 2017. e-Pub 2017. PMID: 27941539.
Kadara H, Choi M, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Yoo Y, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Wistuba II, Herbst RS. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol 28(1):75-82, 2017. e-Pub 2017. PMID: 27687306.
Choi M, Kadara H, Zhang J, Parra ER, Rodriguez-Canales J, Gaffney SG, Zhao Z, Behrens C, Fujimoto J, Chow C, Kim K, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons DL, Heymach J, Kaftan E, Townsend JP, Lynch TJ, Schlessinger J, Lee J, Lifton RP, Herbst RS, Wistuba II. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol 28(1):83-89, 2017. e-Pub 2017. PMID: 28177435.
Sepesi B, Cuentas EP, Canales JR, Behrens C, Correa AM, Vaporciyan A, Weissferdt A, Kalhor N, Moran C, Swisher S, Wistuba I. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. Semin Thorac Cardiovasc Surg 29(3):408-415, 2017. e-Pub 2017. PMID: 29195578.
Weissferdt A, Kalhor N, Moran CA. Pleuromediastinal Epithelial-Myoepithelial Carcinomas: A Clinicopathologic and Immunohistochemical Study of Two Cases. Am J Clin Pathol 146(6):736-740, 2016. e-Pub 2016. PMID: 27864182.
Weissferdt A, Kalhor N, Correa AM, Moran CA. "Sarcomatoid" carcinomas of the lung: a clinicopathologic study of 86 cases with a new perspective on tumor classification. Hum Pathol. e-Pub 2016. PMID: 27993578.
Weissferdt A, Kalhor N, Moran CA. Intrathoracic glomus tumors and glomangiosarcomas: a clinicopathological and immunohistochemical study of 14 cases with emphasis on anatomic distribution. Virchows Arch 469(5):541-546, 2016. e-Pub 2016. PMID: 27591766.
Weissferdt A, Kalhor N, Petersson F, Moran CA. Ectopic Hamartomatous Thymoma-New Insights Into a Challenging Entity: A Clinicopathologic and Immunohistochemical Study of 9 Cases. Am J Surg Pathol 40(11):1571-1576, 2016. e-Pub 2016. PMID: 27428736.
Weissferdt A, Kalhor N, Rodriguez Canales J, Fujimoto J, Wistuba II, Moran C. Primary Mediastinal Yolk Sac Tumors: An Immunohistochemical Analysis of 14 Cases. Appl Immnohistochem Mol Morphol, 2016. e-Pub 2016. PMID: 27643524.
Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. e-Pub 2016. PMID: 27480147.
Weissferdt A, Kalhor N, Canales JR, Fujimoto J, Wistuba II, Moran CA. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases. Hum Pathol. e-Pub 2016. PMID: 27569293.
Padanad MS, Konstantinidou G, Venkateswaran N, Melegari M, Rindhe S, Mitsche M, Yang C, Batten K, Huffman KE, Liu J, Tang X, Rodriguez-Canales J, Kalhor N, Shay JW, Minna JD, McDonald J, Wistuba II, DeBerardinis RJ, Scaglioni PP. Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis. Cell Rep. e-Pub 2016. PMID: 27477280.
Weissferdt A, Kalhor N, Moran CA. Thymomas With Extensive Clear Cell Component: A Clinicopathologic and Immunohistochemical Study of Nine Cases. Am J Clin Pathol 146(1):132-6, 2016. e-Pub 2016. PMID: 27371363.
Parra ER, Behrens C, Rodriguez-Canales J, Lin HY, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients. Clin Cancer Res. e-Pub 2016. PMID: 27252415.
Weissferdt A, Kalhor N, Moran CA. Sebaceous Lymphadenoma of The Thymus A clinicopathological and immunohistochemical study of two cases. Hum Pathol. e-Pub 2016. PMID: 27374279.
Jakubek Y, Lang W, Vattathil S, Garcia M, Xu L, Huang L, Yoo SY, Shen L, Lu W, Chow CW, Weber Z, Davies G, Huang J, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran R, El-Zein R, Swisher SG, Wang J, Fowler J, Spira AE, Ehli EA, Wistuba II, Scheet P, Kadara H. Genomic landscape established by allelic imbalance in the cancerization field of a normal appearing airway. Cancer Res. e-Pub 2016. PMID: 27216194.
Weissferdt A, Kalhor N, Moran CA. Cystic well differentiated squamous cell carcinoma of the thymus A clinicopathological and immunohistochemical study of 6 cases. Histopathology 68(3):333-8, 2016. e-Pub 2016. PMID: 26031186.
Riquelme E, Behrens C, Lin HY, Simon G, Papadimitrakopoulou V, Izzo J, Moran C, Kalhor N, Lee JJ, Minna JD, Wistuba II. Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations. Cancer Res 76(3):675-85, 2016. e-Pub 2016. PMID: 26676756.
Falk N, Weissferdt A, Kalhor N, Moran CA. Primary Pulmonary Salivary Gland-type Tumors: A Review and Update. Adv Anat Pathol 23(1):13-23, 2016. e-Pub 2016. PMID: 26645458.
Wang J, Kalhor N, Hu J, Wang B, Chu H, Zhang B, Guan Y, Wu Y. Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer. PLoS One 11(10):e0163397, 2016. e-Pub 2016. PMID: 27695079.
Zhang YA, Ma X, Sathe A, Fujimoto J, Wistuba II, Lam S, Yatabe Y, Wang YW, Stastny V, Gao B, Larsen JE, Girard L, Liu X, Song K, Behrens C, Kalhor N, Xie Y, Zhang MQ, Minna JD, Gazdar AF. Validation of SCT Methylation As a Hallmark Biomarker for Lung Cancers. J Thorac Oncol. e-Pub 2015. PMID: 26725182.
Liu W, Hu S, Konopleva M, Khoury JD, Kalhor N, Tang G, Bueso-Ramos CE, Jorgensen JL, Lin P, Medeiros LJ, Lu X. De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis. Pediatr Hematol Oncol:1-13. e-Pub 2015. PMID: 26558423.
Piña-Oviedo S, Weissferdt A, Kalhor N, Moran CA. Primary Pulmonary Lymphomas. Adv Anat Pathol 22(6):355-75, 2015. e-Pub 2015. PMID: 26452211.
Weissferdt A, Kalhor N, Moran C. Primary thymic cholesteroloma: a clinicopathological correlation of four cases of an unusual benign lesion. Virchows Arch 467(5):609-11, 2015. e-Pub 2015. PMID: 26266777.
Song S, Honjo S, Jin J, Chang SS, Scott AW, Chen Q, Kalhor N, Correa AM, Hofstetter WL, Albarracin CT, Wu TT, Johnson RL, Hung MC, Ajani JA. The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. Clin Cancer Res 21(11):2580-90, 2015. e-Pub 2015. PMID: 25739674.
Zenali MJ, Weissferdt A, Solis LM, Ali S, Tang X, Mehran RJ, Wistuba II, Moran CA, Kalhor N. An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung. Hum Pathol 46(6):836-42, 2015. e-Pub 2015. PMID: 25776025.
Weissferdt A, Kalhor N, Moran CA. Ewing sarcoma with extensive neural differentiation: a clinicopathologic, immunohistochemical, and molecular analysis of three cases. Am J Clin Pathol 143(5):659-64, 2015. e-Pub 2015. PMID: 25873499.
Guo C, Hao C, Shao R, Fang B, Correa AM, Hofstetter WL, Roth JA, Behrens C, Kalhor N, Wistuba II, Swisher SG, Pataer A. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget 6(13):11114-24, 2015. e-Pub 2015. PMID: 25798539.
Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346(6206):256-9, 2014. e-Pub 2014. PMID: 25301631.
Weissferdt A, Kalhor N, Liu H, Rodriguez J, Fujimoto J, Tang X, Wistuba II, Moran CA. Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases. Hum Pathol. e-Pub 2014. PMID: 25294372.
Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer 85(1):88-93, 2014. e-Pub 2014. PMID: 24792335.
Kalhor N. Colloid carcinoma of the lung: Current views. Semin Diagn Pathol 31(4):265-70, 2014. e-Pub 2014. PMID: 25239272.
Weissferdt A, Kalhor N, Moran C. Lung Carcinoma: Beyond the WHO classification. Semin Diagn Pathol 31(4):259, 2014. e-Pub 2014.
Weissferdt A, Kalhor N, Moran CA. Lung carcinoma: Beyond the WHO classification. Semin Diagn Pathol. e-Pub 2014. PMID: 25002355.
Weissferdt A, Kalhor N, Moran CA. Combined thymoma-thymic seminoma. Report of 2 cases of a heretofore unreported association. Hum Pathol. e-Pub 2014. PMID: 25090916.
Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, Garcia MM, Chow CW, Chu Z, Mendoza G, Shen L, Kalhor N, Hong WK, Moran C, Wang J, Spira A, Coombes KR, Wistuba II. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. J Natl Cancer Inst 106(3):dju004, 2014. e-Pub 2014. PMID: 24563515.
Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerkel GA, Medeiros LJ, Luthra R, Patel KP. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol 27(2):314-27, 2014. e-Pub 2014. PMID: 23907151.
Hellmann MD, Chaft JE, William WN, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, Collaborative Group UOTMALC. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol 15(1):e42-50, 2014. e-Pub 2014. PMID: 24384493.
Almeida MF, Patnana M, Korivi BR, Kalhor N, Marcal L. Ewing sarcoma of the kidney: a rare entity. Case Rep Radiol 2014:283902, 2014. e-Pub 2014. PMID: 24523977.
Behrens C, Solis Soto LM, Lin HY, Yuan P, Tang X, Kadara H, Riquelme E, Galindo H, Moran C, Kalhor N, Swisher SG, Simon G, Stewart DJ, Lee JJ, Wistuba II. EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma. Clin Cancer Res 19(23), 2013. e-Pub 2013. PMID: 24097870.
Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES. Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma. Clin Cancer Res 19(22). e-Pub 2013. PMID: 24048333.
Weissferdt A, Kalhor N, Moran CA. Well-differentiated adenocarcinoma-bronchioloalveolar carcinoma-in situ adenocarcinoma: a conundrum. Adv Anat Pathol 20(5):347-351, 2013. e-Pub 2013. PMID: 23939151.
Weissferdt A, Kalhor N, Marom EM, Benveniste MF, Godoy MC, Correa AM, Swisher SG, Moran CA. Early-stage pulmonary adenocarcinoma (T1N0M0): a clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience. Mod Pathol 26(8):1065-1075, 2013. e-Pub 2013. PMID: 23542459.
David E, Thall PF, Kalhor N, Hofstetter WL, Rice DC, Roth JA, Swisher SG, Walsh GL, Vaporciyan AA, Wei C, Mehran RJ. Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size. Ann Thorac Surg 95(6):1872-1877, 2013. e-Pub 2013. PMID: 23643547.
Kalhor N, Wistuba II. Perfecting the fine-needle aspirate cell block. Cancer Cytopathol 121(3):109-10, 2013. e-Pub 2013. PMID: 23614136.
Kalhor N. Perfecting the Cell Block. Cancer Cytopathology 121(3):109-110, 2013. e-Pub 2013.
William WN, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, Research Group UOTMALCC. Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non-Small-Cell Lung Cancer after Neoadjuvant Chemotherapy. J Thorac Oncol 8(2):222-8, 2013. e-Pub 2013. PMID: 23287849.
Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R, Wistuba II. g-Protein Coupled Receptor Family C, Group 5, Member A (gprc5a) Expression Is Decreased in the Adjacent Field and Normal Bronchial Epithelia of Patients with Chronic Obstructive Pulmonary Disease and Non-Small-Cell Lung Cancer. J Thorac Oncol 7(12):1747-54, 2012. e-Pub 2012. PMID: 23154545.
Kalhor N, Moran CA. Thymoma: current concepts. Oncology (Williston Park) 26(10):975-81, 2012. e-Pub 2012. PMID: 23176011.
Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov 2(9):798-811, 2012. e-Pub 2012. PMID: 22961666.
Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Tissue Platinum Concentration and Tumor Response in Non-Small-Cell Lung Cancer. J Clin Oncol. e-Pub 2012. PMID: 22891266.
Solis LM, Behrens C, Raso MG, Lin HY, Kadara H, Yuan P, Galindo H, Tang X, Lee JJ, Kalhor N, Wistuba II, Moran CA. Histologic patterns and molecular characteristics of lung adenocarcinoma associated with clinical outcome. Cancer 118(11):2889-99, 2012. e-Pub 2012. PMID: 22020674.
Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Hofstetter W, Kalhor N, Lee JJ, Franklin W, Stewart DJ, Wistuba II. High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and Mutation. J Thorac Oncol 7(5):833-840, 2012. e-Pub 2012. PMID: 22729036.
Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba II, Swisher SG. Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy. J Thorac Oncol 7(5):825-832, 2012. e-Pub 2012. PMID: 22481232.
Moran CA, Weissferdt A, Kalhor N, Solis LM, Behrens C, Wistuba II, Suster S. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the world health organization schema. Am J Clin Pathol 137(3):444-50, 2012. e-Pub 2012. PMID: 22338057.
Kalhor N, Suster S, Moran CA. Primary Pulmonary Chondrosarcomas: A clinicopathologic study of 4 cases. Hum Pathol 42(11):1629-34, 2011. e-Pub 2011. PMID: 21496864.
Tsuta K, Kalhor N, Wistuba II, Moran CA. Clinicopathological and immunohistochemical analysis of spindle-cell carcinoid tumour of the lung. Histopathology 59(3):526-36, 2011. e-Pub 2011. PMID: 22034892.
Tsuta K, Liu DC, Kalhor N, Wistuba II, Moran CA. Using the mitosis-specific marker anti-phosphohistone h3 to assess mitosis in pulmonary neuroendocrine carcinomas. Am J Clin Pathol 136(2):252-9, 2011. e-Pub 2011. PMID: 21757598.
Weissferdt A, Hernandez JC, Kalhor N, Moran CA. Spindle Cell Thymomas: An Immunohistochemical Study of 30 Cases. Appl Immunohistochem Mol Morphol 19(4):329-35, 2011. e-Pub 2011. PMID: 21386704.
Tsuta K, Kalhor N, Raso MG, Wistuba II, Moran CA. Oncocytic neuroendocrine tumors of the lung: histopathologic spectrum and immunohistochemical analysis of 15 cases. Hum Pathol 42(4):578-85, 2011. e-Pub 2011. PMID: 21329962.
Kalhor N, Suster S, Moran CA. Spindle Cell Thymomas (WHO Type A) With Prominent Papillary and Pseudopapillary Features: A Clinicopathologic and Immunohistochemical Study of 10 Cases. Am J Surg Pathol 35(3):372-7, 2011. e-Pub 2011. PMID: 21317709.
Weissferdt A, Kalhor N, Suster S. Malignant mesothelioma with prominent adenomatoid features: a clinicopathologic and immunohistochemical study of 10 cases. Ann Diagn Pathol 15(1):25-9, 2011. e-Pub 2011. PMID: 21106421.
Tsuta K, Raso MG, Kalhor N, Liu DC, Wistuba II, Moran CA. Sox10-positive sustentacular cells in neuroendocrine carcinoma of the lung. Histopathology 58(2):276-85, 2011. e-Pub 2011. PMID: 21323953.
Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba II, Moran CA. Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer 71(1):34-41, 2011. e-Pub 2011. PMID: 20462655.
Weissferdt A, Kalhor N, Suster S, Moran CA. Primary angiosarcomas of the anterior mediastinum: A clinicopathologic and immunohistochemical study of 9 cases. Hum Pathol 41(12):1711-7, 2010. e-Pub 2010. PMID: 20709359.
Moran CA, Kalhor N, Suster S. Invasive spindle cell thymomas (WHO Type A): a clinicopathologic correlation of 41 cases. Am J Clin Pathol 134(5):793-8, 2010. e-Pub 2010. PMID: 20959663.
Weissferdt A, Kalhor N, Suster S, Moran CA. Adenomatoid spindle cell thymomas: a clinicopathological and immunohistochemical study of 20 cases. Am J Surg Pathol 34(10):1544-9, 2010. e-Pub 2010. PMID: 20852406.
Kalhor N, Marom EM, Moran CA. Primary myxoma of the lung. Ann Diagn Pathol 14(3):178-81, 2010. e-Pub 2010. PMID: 20471563.
Kalhor N, Suster S, Moran CA. Primary sclerosing neuroendocrine carcinomas of the lung: A clinicopathologic and immunohistochemical study of 10 cases. Am J Clin Pathol 133(4):618-22, 2010. e-Pub 2010. PMID: 20231615.
Kalhor N, Staerkel GA, Moran CA. So-called sclerosing hemangioma of lung: current concept. Ann Diagn Pathol 14(1):60-7, 2010. e-Pub 2010. PMID: 20123460.
Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA. Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol 133(1):133-40, 2010. e-Pub 2010. PMID: 20023269.
Kalhor N, Moran. Primary Mediastinal Neuroendocrine Tumors. Diagnostic Histopathology 16(5):237-242, 2010. e-Pub 2010.
Gustafson S, Medeiros LJ, Kalhor N, Bueso-Ramos CE. Anaplastic large cell lymphoma: another entity in the differential diagnosis of small round blue cell tumors. Ann Diagn Pathol 13(6):413-27, 2009. e-Pub 2009. PMID: 19917480.
Kalhor N, Ramirez PT, Deavers MT, Malpica A, Silva EG. Immunohistochemical studies of trophoblastic tumors. Am J Surg Pathol 33(4):633-8, 2009. e-Pub 2009. PMID: 19145204.
Deavers MT, Kalhor N, Silva EG. Diagnostic problems with trophoblastic lesions. Arch Pathol Lab Med 132(2):168-74, 2008. e-Pub 2008. PMID: 18251570.
Kalhor N, Zander DS, Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol 19(8):1117-23, 2006. e-Pub 2006. PMID: 16680154.

Professional Educational Materials

. Comprehensive Review of Thoracic Pathology. Video Conference. The Oakstone Institute, 2014.
. Thoracic chapter, Pathology Grossing Manual, 2010-2012.

Abstracts

Guerrouahen B, Kalhor N, Wistuba I, Parra E, Wang W, Mantha G, Reddy N, Famobio T, Walters K, Contreras A. Tissue-Based Multiplexing, Multispectral Immunofluorescence Testing in a CLIA-Like Laboratory Environment: A Step Forward Towards Clinical Testing. Mod Pathol 104(3):S1784-85, 2024. e-Pub 2024.
Ye Q, Liu A, Estrella J, Kalhor N, Albarracin CT, Ding Q, Wu Y. TRPS1 Expression in Neuroendocrine Neoplasms of Breast and Other Organs. Laboratory Investigation 103(3):S237-S237, 2023. e-Pub 2023.
Rojas Alvarez F, Chen P, Serrano A, Fujimoto J, Hong L, Zhu B, Hu X, Salehjahromi M, Bandyopadhyay R, Aminu M, N|| K, Wistuba I, Zhang J, Wu J, Solis Soto L. Artificial Intelligence-Assisted Tissue Morphology Analysis Reveals the Lymphocytes Infiltration Progression from Lung Preneoplasia to Invasive Adenocarcinoma. Mod Pathol 103(3):S1655-56, 2023. e-Pub 2023.
Ye Q, Liu A, Estrella J, N|| K, Albarracin C, Ding QQ, Wu Y. TRPS1 Expression in Neuroendocrine Neoplasms of Breast and Other Organs. Mod Pathol 103(3):S237, 2023. e-Pub 2023.
Parra E, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Zhang J, Gibbons D, Heymach J, Sepesi B, Swisher S, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba I. Image Analysis–based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non–small Cell Lung Carcinoma Patients:1-12, 2016. e-Pub 2016.
Choi M, Kadara H, Zhang J, Parra Cuentas E, Rodriguez Canales J, Gaffney S, Zhao ZM, Behrens C, Fujimoto J, Chow CW, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D, Heymach J, Kaftan E, Townsend J, Lynch T, Schlessinger J, Lee JJ, Lifton R, Herbst R, Wistuba I. Mutation and immune profiles in early-stage lung squamous cell carcinoma. Cancer Research 76(14 Suppl), 2016. e-Pub 2016.
Shien K, Ruder D, Ileana E, Papadimitrakopoulou V, Frampton G, Behrens C, Kalhor N, Lee JJ, Tang X, Herbst RS, Wistuba I, Izzo J. Detection of a novel ALK fusion variant in lung adenocarcinoma using a comprehensive genomic analysis. Cancer Research 76(14 Suppl), 2016. e-Pub 2016.
Kadara H, Choi M, Zhang J, Parra Cuentas E, Rodriguez Canales J, Gaffney S, Zhao ZM, Behrens C, Fujimoto J, Chow CW, Kalhor N, Moran C, Rimm D, Swisher S, Gibbons D, Heymach J, Kaftan E, Townsend J, Lynch T, Schlessinger J, Lee JJ, Lifton R, Wistuba I, Herbst R. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma. Cancer Research 76(Issue Suppl), 2016. e-Pub 2016.
Ramineni M, Weissferdt A, FRCPATH, Swisher S, Moran C, Kalhor N. Combined High-Grade Neuroendocrine Lung Carcinomas: A Clinicopathologic Study of Surgical Resection Cases from a Single Institution, 2016. e-Pub 2016.
Villalobos P, Gold K, Parra E, Mino B, Rodriguez-Canales J, Mehran R, Moran C, Wistuba I, Heymach J, Glisson B, Kalhor N. Expression of Programmed Death-Ligand 1 in Small Cell Lung Cancer: Analysis of 48 Cases, 2016. e-Pub 2016.
Kalhor N, Xu G, Salem A, Fujimoto J, Stingo F, Glisson B, Mehran R, Yao J, Moran C. Prognostic Factors and Recurrence in Primary Lung Carcinoid Tumor Treated at a Single Institution, 2016. e-Pub 2016.
Kalhor N, Guoping X, Fujimoto J, Hoff R, Tiemeny P, Wagner S, Mehran R, Moran C, Wistuba I. Cell Cycle Progression Score is a Promising Predictor of Recurrence in Primary Lung Carcinoid Tumors, 2016. e-Pub 2016.
Ruder D, Papadimitrakopoulou V, Shien K, Kalhor N, Lee JJ, Hong W, Tang X, Girard L, Minna J, Diao L, Wang J, Hanson N, Sun J, Miller V, Frampton G, Herbst R, Wistuba I, Izzo J. Rictor alterations elicit non-canonical signaling mechanisms contributing to tumorigenicity and therapeutic resistance in non-small cell lung cancer (NSCLC). Cancer Research 75(15 Suppl), 2015. e-Pub 2015.
Shien K, Vassiliki A, Papadimitrakopoulou, Ruder D, Hanson N, Kalhor N, Lee JJ, Hong WK, Tang X, Herbst RS, Girard L, Minna J, Kurie J, Wistuba I, Izzo J. Oncostatin M receptor activation leads to molecular targeted therapy resistance in non-small cell lung cancer. Cancer Research 75(15 Suppl), 2015. e-Pub 2015.
Gomez DR, Diao L, Wang J, Wistuba I, Moran C, Kalhor N, Suraokar MB, Swisher SG, Behrens C, Fan Y, Heymach JV, Byers LA. Neoadjuvant chemotherapy is associated with increased expression of DNA repair proteins and epithelial to mesenchymal transition (EMT) in patients with non-small cell lung cancer (NSCLC). Cancer Research 75(Suppl 15):3623-3623, 2015. e-Pub 2015.
Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Lou Y, Gibbons DL, Heymach JV, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Lee JJ, Kadara H, Moran C, Wistuba II. High programmed cell death ligand 1 expression and low immune infiltrate score correlate with worse outcome in patients with lung adenocarcinoma. Cancer Research 75(Suppl 15):4526-4526, 2015. e-Pub 2015.
Jakubek Y, Lang W, Vattathil S, Garcia M, Huang L, Lu W, Chow CW, Weber Z, Davies GE, Behrens C, Kalhor N, Moran C, Fujimoto J, Mehran RJ, Fowler J, Ehli EA, Wistuba II, Scheet P, Kadara H. The landscape of DNA allelic imbalance in the normal-appearing airway field of cancerization. Cancer Research 75(Suppl 15), 2015. e-Pub 2015.
Parra ER, Behrens C, Rodriguez-Canales J, Lin H, Mino B, Blando J, Lou Y, Gibbons DL, Heymach JV, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Lee JJ, Kadara H, Moran C, Wistuba II. High Programmed Cell Death Ligand 1 Expression and Low Immune Infiltrate Score Correlate with Worse Outcome in Patients with Lung Adenocarcinoma. Cancer Research(15 Supplement):4256-4256, 2015. e-Pub 2015.
Kusko R, Anderlind C, Wang G, Zhang S, Wallace WD, Waslter T, Ebright M, Garcia M, Eisenberg R, Lee G, Liu G, Elashoff D, Kalhor N, Moran C, Mehran R, Fujimoto J, Massion P, Dubinett S, Wistuba I, Lenburg M, Kadara H, Spira A. Mapping the airway-wide molecular field of injury in smokers with lung cancer. Cancer Research 74(19 Suppl), 2014. e-Pub 2014.
Maki Y, Fujimoto J, Yoo SY, Garcia M, Gower A, Shen L, Chow CW, Behrens C, Kalhor N, Moran C, Wang J, Spira A, Coombes K, Wistuba I, Kadara H. Transcriptomic architecture of the field of cancerization in the adjacent normal-appearing airway: Early mechanisms in lung carcinogenesis. Cancer Research 74(19 Suppl), 2014. e-Pub 2014.
Liu H, Mino B, Parra E, Fujimoto J, Tang X, Weissferdt, Kalhor N, Wistuba II, Moran CA. Effects of Slide Storage on PTEN Antigenicity: Implications for Clinical Trials and Translational Research, 2014. e-Pub 2014.
Fujimoto J, Zhang J, Pickering CR, Kadara H, Liu CG, Drummond JA, Muzny DM, Doddapaneni H, Weissferdt A, Wheeler DA, Myers JN, Wang J, Wistuba II, Kalhor N, Moran CA. Identification of Novel Somatic Variants in Thymic Epithelial Tumors by Next-Generation Sequencing, 2014. e-Pub 2014.
Mino B, Roy-Chowdhuri S, Gonzalez I, Kiriakova G, Liu H, Fujimoto J, Tang X, Weissferdt A, Kalhor N, Wistuba II, Moran CA, Rodriguez-Canales J. Optimization of a Cell Transfer Technique for Multiple Immunocytochemistry from Single Cytology Smears for Pathology and Translational Research, 2014. e-Pub 2014.
Weissferdt A, Kalhor N, Liu H, Rodriguez J, Fujimoto J, Tang X, Wistuba II, Moran CA. Paraganglioma Versus Thymic Carcinoid Tumor: An Immunohistochemical Study of 46 Cases, 2014. e-Pub 2014.
Weissferdt A, Kalhor N, Liu H, Rodriguez, Fujimoto J, Tang X, Wistuba II, Moran CA. Primary Mediastinal Seminomas: A Comprehensive Immunohistochemical Study Using Novel Markers, 2014. e-Pub 2014.
Mann SE, Moran CA, Kalhor N. Localized Malignant Epitheloid Mesothelioma, 2014. e-Pub 2014.
Maki U, Fujimoto J, Yoo SY, Gower A, Shen L, Garcia M, Kabbout M, Chow CW, Ki Hong W, Kalhor N, Wang J, Moran C, Spira A, Coombes KR, Wistuba II, Kadara H. Transcriptomic architecture of the airway field cancerization in early-stage non-small cell lung cancer. 104th Annual American Association for Cancer Research (AACR) Meeting 73(8 Suppl), 2013. e-Pub 2013.
Weissferdt A, Kalhor N, Moran CA. Comparative Immunohistochemical Analysis of Pulmonary and Thymic Neuroendocrine Carcinomas Using Pax8 and TTF-1, 2013. e-Pub 2013.
Kalhor N, Fujimoto J, Rodriguez J, Byers LA, Kies MS, Hofstetter WL, El-Naggar AK, Bell D. MECT1-MAML2 Fusion Transcript Expression in Lung Mucoepidermoid Carcinoma, 2013. e-Pub 2013.
Papadimitrakopoulou V, Wistuba II, Lee J, Tsao AS, Kalhor N, Fossella F, Heymach J, Alden CM, Gettinger SN, Coombes KR, Saintigny P, Tang X, Duffield E, Boyer J, Davis SE, Powis G, Mauro DJ, Rubin EH, Ki Hong W, Herbst RS. BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC). ASCO 49th Annual Meeting. Chicago IL, 2013. e-Pub 2013.
Kilari D, Tang X, Chow C, Fujimoto J, Kalhor N, Swisher S, Wistuba II, Stewart DJ, Siddik ZH, Kim ES. Copper transporter CTR1 expression and tissue platinum concentration in NSCLC. ASCO 49th Annual Meeting. Chicago IL, 2013. e-Pub 2013.
William WN, Erickson H, Wei C, Hanson N, Tang X, Rodriguez J, Kalhor N, Lee J, Ki Hong W, Kim E, Wistuba II. Differences in mutation patterns of diagnostic versus post-chemotheraphy samples in patients with metastatic non-small cell lung cancer (NSCLC). ASCO 49th Annual Meeting, Chicago IL, 2013. e-Pub 2013.
Sepesi B, Correa AM, Pataer A, Kalhor N, Bekele NB Erasmus JJ, Heymach J, Hofstetter WL, Wistuba II, Swisher SG, Moonshot Group TUOTMALC. The Impact of Histopathologic Response on Pathologic TNM Lung Cancer Staging System (AJCC 7th) Following Neoadjuvant Chemotherapy. Society of Thoracic Surgeons 49th Annual Meeting, 2013. e-Pub 2013.
Tang X, Xue Y, Su X, Harun N, Cai Y, Behrens C, Papadimitrakopoulou V, Blowers D, Moran C, Kalhor N, Rice D, Beran G, Lee J, Kilgour E, Wistuba II. Fibroblast growth factor receptor 1 (FGFR1) gene copy number gain in adenocarcinoma and squamous cell carcinoma of the lung. ASCO 49th Annual Meeting, Chicago, IL, 2013. e-Pub 2013.
Wk H, Kalhor N, Moran C, Wistuba II. Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential targets for chemoprevention in early stage lung cancer patients. 103rd Annual American Association for Cancer Research (AACR) 72(8 Suppl), 2012. e-Pub 2012.
Fujimoto J, Kadara H, Woo SK, Garcia M, Kabbout M, Basey A, Wang J, Coombes KR, Kim ES, Hong WK, Kalhor N, Moran C, Wistuba II. Gene expression profiling of lung field cancerization reveals potential targets for chemoprevention, 2012. e-Pub 2012.
Bhardwaj V Likhacheva A, Byers L, Diao L, Allen P, Minna J, Ihle N, Powis G, Das A, Girard L, Peyton M, Yordy J, Liao Z, Ang K, Story M, Kalhor N, Komaki R, Kim E, Heymach J, Welsh J. Establishing role of KRAS mutation on NSCLC radio-sensitivity. Cancer Research 72(8 Suppl), 2012. e-Pub 2012.
Kim E, He G, Chow CW, Fujimoto J, Lee JJ, Kalhor N, Swisher S, Wistuba I, Stewart D, Siddik Z. Tissue platinum concentration and tumor response in non-small cell lung cancer. Clin Can Res 18(3 Suppl), 2012. e-Pub 2012.
Godoy M, Boonsirikamchai P, Marom E, Truong M, Naidich D, Kalhor N, Moran C. Adenocarcinoma: Radiologic-Pathologic Correlation. e-Pub 2012.
Kalhor N, Tang X, Kim ES, Padadimitrakopulou V, Lee JJ, Herbst RS, Alden CM, Erickson HS, Moran CA, Tam AL, Gupta S, Lippman SM, Hong WK, Wistuba II. Feasibility of Molecular Testing in Patients with Chemorefractory Non-Small Cell Carcinoma, 2012. e-Pub 2012.
Kim ES, Chow CW, Kalhor N, Fujimoto J, Swisher SG, Wistuba II, Stewart DJ, Siddik Z. Correlation between Tissue Platinum Concentration and Tumor Response in NSCLC, 2011. e-Pub 2011.
Galindo HG, Suraokar M, Behrens C, Woods DM, Kalhor N, Aldape KD, Fujimoto J, Herbst RS, Erickson HS, Wistuba II. Identification of prostate stem cell antigen (PSCA) as a potential marker for lung cancer brain metastasis 71(8), 2011. e-Pub 2011.
Nunez MI, Behrens C, Woods DM, Lin H, Suraokar M, Kadara H, Minna JD, Hofstetter W, Kalhor N, Hong WK, Lee JJ, Franklin W, Stewart D, Wistuba II. High Expression of Folate Receptor Alpha in Lung Cancer Correlates with Adenocarcinoma Histology and EGFR Mutation. 100th Annual Meeting, The United States and Canadian Academy of Pathology. Mod Pathol 24(Suppl1):420A (#1788), 2011. e-Pub 2011.
Guo M, Si Q, Gong Y, Kalhor N, Chen S, Moran C. EGFR Mutations in Exons 18, 19 and 21 Are Closely Associated with TTF-1 Positive Lung Adenocarcinoma. 100th Annual Meeting, The United States and Canadian Academy of Pathology. Mod Pathol 24(Suppl 1):411A (#1749), 2011. e-Pub 2011.
Zenali M, Deavers MT, Kalhor N, Prieto VG. Malignant Mesothelioma Expresses Melan-A (A-103), a Possible Diagnostic Pitfall. 100th Annual Meeting, The United States and Canadian Academy of Pathology. Mod Pathol 24(Suppl 1):429A (#1826), 2011. e-Pub 2011.
Solis LM, Raso MG, Fujimoto J, Behrens C, Woods DM, Mendoza G, Kalhor N, Moran CA, Wistuba II. Molecular abnormalities associated to the progression of lung adenocarcinomas with BAC features from non-invasive to invasive patterns, 2011. e-Pub 2011.
Weissferdt A, Kalhor N, Suster S, Moran CA. Pleural malignant mesothelioma with prominent adenomatoid features: clinicopathological and immunohistochemical analysis of 10 cases. XXVIIIth International Congress of the International Academy of Pathology. Histopathology 57(Suppl 1):219 (#607), 2010. e-Pub 2010.
Weissferdt A, Hernandez JC, Kalhor N, Moran CA. Pancytokeratin, cytokeratin 5/6, cytokeratin 7, cytokeratin 20, TTF-1 and p63 as a diagnostic tool separating non-small cell carcinomas in biopsy specimens. XXVIIIth International Congress of the International Academy of Pathology. Histopathology 57(Suppl 1):221 (#611), 2010. e-Pub 2010.
Weissferdt A, Hernandez-Prera JC, Kalhor N, Moran CA. Spindle cell thymomas: an immunohistochemical study of 30 cases. XXVIIIth International Congress of the International Academy of Pathology. Histopathology 57(Suppl 1):240 (#667), 2010. e-Pub 2010.
Zenali M, Soto LMS, Roso G, Wistuba II, Moran CA, Kalhor N. Mucinous Carcinoma (Colloid Carcinoma) of the Lung, an Immunohistochemical and Molecular Analysis. 99th Annual Meeting, The United States and Canadian Academy of Pathology. Mod Pathol 23(Suppl1):416A (#1860), 2010. e-Pub 2010.

Book Chapters

Wessferdt A, Kalhor N, Moran CA. Diagnostic Immunohistochemistry: Theranostic and genomic applications. 5th. Elsevier Saunders, 2017.
Kalhor N, Moran CA. "Extrinsic Allergic Alveolitis" and Eosinophilic Pneumonia". In: Diagnostic Pathology, Non-neoplastic Pediatrics. AMIRSYS Publishing, 2013.
Kalhor N, Moran CA. “Pathology of Neuroendocrine Tumors”. In: Neuroendocrine Tumors (Current Clinical Oncology). Humana Press, 2011.
Kalhor N Moran CA. "Immunological and molecular studies in lung cancer”. In: Immunological & Molecular Diagnosis of Cancer. Nova Publishers, 2010.
Shroff GS, Kalhor N, Mehran RJ, de Groot PM, Carter BW. Staging of Small Cell Lung Cancer. In: Diagnostic Imaging for Thoracic Surgery - A Manual for Surgeons and Radiologists.

Books (edited and written)

Kalhor N, Moran CA, Weissferdt A. Oncological Surgical Pathology. Springer, 2020.
Kalhor N, Moran CA. Mediastinal Pathology. Springer, 2019.
Moran CA, Suster S. Medical editor for book of “Diagnostic Pathology: Thoracic. Amirsys Inc, 2011.

Less

CV information above last modified March 06, 2026

Neda Kalhor, M.D.

About Dr. Neda Kalhor

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Professional Educational Materials

Abstracts

Book Chapters

Books (edited and written)

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Neda Kalhor, M.D.

About Dr. Neda Kalhor

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Licenses & Certifications

Experience & Service

Faculty Academic Appointments

Administrative Appointments/Responsibilities

Other Professional Positions

Extramural Institutional Committee Activities

Professional Memberships

Selected Presentations & Talks

Local Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Selected Publications

Peer-Reviewed Articles

Professional Educational Materials

Abstracts

Book Chapters

Books (edited and written)

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Shop UT MD Anderson